Simvastatin – 25 mg

Brand:
Cayman
CAS:
79902-63-9
Storage:
-20
UN-No:
Non-Hazardous - /

Simvastatin is a competitive inhibitor of HMG-CoA reductase with a Ki value of 0.12 nM for the hydrolyzed, open ring form of the molecule.{15312} After 18 days of treatment with simvastatin in dogs at a dose of 8 mg/kg/day, plasma cholesterol levels were reduced by 33%.{15310} Simvastatin also suppresses TNF-induced NF-κB activation (IC50 ~ 13 µM), which potentiates apoptosis in human myeloid leukemia cells and thus may be useful in treating cancer.{15363} Clinical formulations containing simvastatin are used in combination with ezetimibe to treat dyslipidemia.  

 

Available on backorder

SKU: 10010344 - 25 mg Category:

Description

A potent, competitive inhibitor of HMG-CoA reductase (Ki = 0.12 nM); 8 mg/kg/day for 18 days reduces plasma cholesterol levels by 33% in dogs; suppresses TNF-induced NF-κB activation (IC50 ~ 13 µM) ,


Formal name: 2,2-dimethyl-1S,2,3R,7S,8S,8aR-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, butanoic acid

Synonyms:  MK-733

Molecular weight: 418.6

CAS: 79902-63-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Sterol Biosynthesis||Product Type|Biochemicals|Small Molecule Inhibitors|TNF-α/NF-κB Signaling||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|NF-κB Signaling||Research Area|Cancer|Transcription Factors|NF-κB||Research Area|Cardiovascular System|Lipids & Lipoproteins|Cholesterol Metabolism||Research Area|Cell Biology|Cell Death|Ferroptosis||Research Area|Cell Biology|Cell Signaling|NF-κB Signaling||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Epigenetics, Transcription, & Translation|Transcription Factors